Navigation Links
Patients with heart failure need specialist care
Date:11/1/2013

New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure.

Heart failure affects 2-3% of the overall population and over 10% of the elderly worldwide, and is associated with high risk for early death and reduced quality of life. Drug therapy improves symptoms and reduces mortality and is well used. However, modern heart failure pacemakers, heart pumps and also heart transplantation are of great benefit in selected patients, but are poorly utilized. Earlier studies have shown that, a major reason is that heart failure patients are generally cared for by generalist doctors with limited awareness of these treatments.

In the present study, a team comprising researchers at Sweden's Karolinska Institutet, Linkping University, Stockholm South General Hospital and Karolinska University Hospital analysed data from 10,000 patients from the large Swedish Heart Failure Registry. First researchers showed that early death in these patients was related to heart failure (rather than for example age) suggesting that better treatment for heart failure would reduce mortality.

Second, the researchers defined 5 risk factors for mortality: poor pump capacity, poor kidney function, low blood count and absent treatment with the drugs ACE inhibitors and beta blockers. If any one of these risk factors was present in a given patient, the mortality was so high that the patient would potentially benefit from a heart failure pacemaker, heart pump and heart transplantation. This risk persisted after adjustment for a large number of other factors, such as patients' age, general health and other factors.

"Currently, less than 5% of patients with heart failure receive heart failure pacemakers and many fewer receive heart pumps or transplantation. Our findings suggest that many more need these treatments and should be referred to heart failure specialists for evaluation", says study leader Dr Lars H. Lund of Karolinska Institutet.

Karolinska Institutet and Stockholm County Council have initiated the cooperative "Project 4D", aiming to improve knowledge building within healthcare and research regarding four diagnoses, among them heart failure. The current study was financed by the Swedish Heart-Lung Foundation, the Stockholm County Council and the Swedish Association of Local Authorities and Regions.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert  

Related medicine news :

1. New Report: The Online Experience of Sarcoma Patients and Supporters
2. Diet Doc Hormone Diets & Weight Loss Plans Reveal Healthy Weight Loss Treatments, Newly Enhanced by a Low Fat Diet, That Help Patients Reach Their Ideal Body Weight
3. Studies: Current hepatitis C treatments cant be used by more than half of patients; others lose opportunity for treatment
4. A Radiology Workflow Solution for Veterinarians and Their Animal Patients Launched
5. Fairfield CT Dentist Utilizes New Technology to Help Patients
6. New York, NY Gum Disease Patients can Now Receive Gentle Gum Disease Surgery with a Laser from Dr. Neda Azadivatan of Precision Periodontics & Dental Implants
7. Mount Sinai Oncologists Improve Quality of Care for Cancer Patients with Standardized Criteria for Palliative Care Consultation
8. Patients Can Avoid Complicated Procedures and Hemorrhoid Surgery with a Painless, 60-Second Procedure Now Offered by Dr. Cynthia Mullen
9. EyeCare 20/20, Short Hills Ophthalmology and the Laser Vision Center of New Jersey to Provide Cataract Surgery To 50 Patients this November
10. Chris Elliott Fund Hosts 2nd Annual Conference, Providing Hope to Brain Cancer and Brain Tumor Patients and Caregivers
11. Overlooked lymph nodes in rib cage have prognostic power for mesothelioma patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patients with heart failure need specialist care
(Date:3/27/2017)... ... March 27, 2017 , ... ... weight management program at Women’s Excellence will help patients lose weight and keep ... exam. The specialists at Women's Excellence will measure BMI, body fat composition, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is ... complicated and require expert user knowledge. In a live webinar on April 11th ... simplified, yet highly accurate, determination of sodium. , It has long been known ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: